Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강주섭 | - |
dc.date.accessioned | 2017-10-30T02:29:15Z | - |
dc.date.available | 2017-10-30T02:29:15Z | - |
dc.date.issued | 2016-01 | - |
dc.identifier.citation | CURRENT PHARMACEUTICAL ANALYSIS, v. 12, NO 2, Page. 107-113 | en_US |
dc.identifier.issn | 1573-4129 | - |
dc.identifier.issn | 1875-676X | - |
dc.identifier.uri | http://www.eurekaselect.com/133430/article | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/30314 | - |
dc.description.abstract | We developed the LC-MS/MS method through a comparison of the pharmacokinetic characteristics of imidapril to assess the bioequivalence of two types of imidapril in 31 normal Korean subjects. Blood samples were collected at 13 time points for 12 h after dosing and detected by LC-MS/MS in the range of 0.2-100 ng/mL with LLOQ of 0.2 ng/mL. Pharmacokinetic parameters analyzed from the plasma samples and data from the reference and test drugs in the plasma were represented such as AUC(0-t) (142.31 vs 131.95 ng.h/mL), AUC(0-infinity) (143.85 vs 133.72 ng.h/mL), C-max(33.28 vs 30.46 ng/mL), T-max(2.0 vs 1.9 h), half-life(1.6 vs 1.6 h), extrapolation (1.35 vs 1.46%), and Ke (0.46 vs 0.45 h(-1)). Pharmacokinetic parameters with a 90% confidence interval (CI) were 0.873-1.084 for AUC(0-t) and 0.863-1.149 for C-max. Pharmacokinetic parameters with 90% CI were included within the bioequivalence range of 80-125% of the KFDA guidelines. Therefore, the two imidapril types were found to be bioequivalent during the fasting state in normal subjects. | en_US |
dc.language.iso | en | en_US |
dc.publisher | BENTHAM SCIENCE PUBL LTD | en_US |
dc.subject | Angiotensin-converting enzyme (ACE) inhibitor | en_US |
dc.subject | bioequivalence | en_US |
dc.subject | imidapril | en_US |
dc.subject | korean volunteers | en_US |
dc.subject | LC-MS/MS | en_US |
dc.subject | Pharmacokinetics | en_US |
dc.title | Quantification of Imidapril in Human Plasma Using the LC-MS/MS Method for Bioequivalence and Pharmacokinetic Studies | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 12 | - |
dc.identifier.doi | 10.2174/1573412911666150723232335 | - |
dc.relation.page | 107-113 | - |
dc.relation.journal | CURRENT PHARMACEUTICAL ANALYSIS | - |
dc.contributor.googleauthor | Lee, Su-Hee | - |
dc.contributor.googleauthor | Kim, Hyun-Jin | - |
dc.contributor.googleauthor | Kim, Shin-Hee | - |
dc.contributor.googleauthor | Park, Yoo-Sin | - |
dc.contributor.googleauthor | Kang, Min-A | - |
dc.contributor.googleauthor | Kim, Do-Wan | - |
dc.contributor.googleauthor | Kang, Ju-Seop | - |
dc.relation.code | 2016006222 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | jskang | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.